The present invention provides for compounds useful for treating an HIV infection, or preventing an HIV infection, or treating AIDS or ARC. The compounds of the invention are of formula I wherein R
1
, R
2
, R
3
, R
4
, R
5a
, R
5b
, R
6a
, R
6b
and X are as herein defined. Also disclosed in the present invention are methods of treating an HIV infection with compounds defined herein and pharmaceutical compositions containing said compounds.
2-(PIPERIDIN-4-YL)-4-PHENOXY-OR PHENYLAMINO-PYRIMIDINE DERIVATIVES AS NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS
申请人:F. Hoffmann-La Roche AG
公开号:EP2089384B1
公开(公告)日:2015-08-05
US7998969B2
申请人:——
公开号:US7998969B2
公开(公告)日:2011-08-16
Exploration of piperidine-4-yl-aminopyrimidines as HIV-1 reverse transcriptase inhibitors. N-Phenyl derivatives with broad potency against resistant mutant viruses
作者:Guozhi Tang、Denis J. Kertesz、Minmin Yang、Xianfeng Lin、Zhanguo Wang、Wentao Li、Zongxing Qiu、Junli Chen、Jianghua Mei、Li Chen、Taraneh Mirzadegan、Seth F. Harris、Armando G. Villaseñor、Jennifer Fretland、William L. Fitch、Julie Qi Hang、Gabrielle Heilek、Klaus Klumpp
DOI:10.1016/j.bmcl.2010.08.068
日期:2010.10
Further investigation of the recently reported piperidine-4-yl-aminopyrimidine class of non-nucleoside reverse transcriptase inhibitors (NNRTIs) has been carried out. Thus, preparation of a series of N-phenyl piperidine analogs resulted in the identification of 3-carboxamides as a particularly active series. Analogs such as 28 and 40 are very potent versus wild-type HIV-1 and a broad range of NNRTI-resistant mutant viruses. Synthesis, structure-activity relationship (SAR), clearance data, and crystallographic evidence for the binding motif are discussed. (c) 2010 Elsevier Ltd. All rights reserved.